OKYO Pharma Limited (OKYO)
| Bid | 1.95 |
| Market Cap | 83.5M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -2.03M |
| EPS (ttm) | -0.12 |
| PE Ratio (ttm) | -18.5 |
| Forward PE | -15.71 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 2.22 |
| Volume | 42,327 |
| Avg. Volume (20D) | 133,888 |
| Open | 2.08 |
| Previous Close | 2.11 |
| Day's Range | 2.02 - 2.22 |
| 52-Week Range | 0.90 - 3.35 |
| Beta | -4.23 |
| Ex-Dividend Date | n/a |
About OKYO
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for OKYO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
3 days ago · proactiveinvestors.com
OKYO Pharma maps out registration path with 100-patient trial of Urcosimod for neuropathic corneal painOKYO Pharma Ltd (NASDAQ:OKYO) plans to run a 100-patient, multi-centre study of its eye-drop candidate Urcosimod in neuropathic corneal pain, laying out a path it hopes can lead to US approval in a co...
2 months ago · proactiveinvestors.com
OKYO Pharma CEO details positive results from Phase 2 urcosimod trial - ICYMIOKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob talked with Proactive about the recently announced topline data from the company's Phase 2 trial evaluating urcosimod in patients with neuropathic corneal ...
2 months ago · proactiveinvestors.com
OKYO Pharma secures $1.9M in non-dilutive funding to advance clinical development of NCP therapyOKYO Pharma Ltd (NASDAQ:OKYO) announced it has secured $1.9 million in non-dilutive funding to support the development of urcosimod, its lead drug candidate for neuropathic corneal pain (NCP). NCP is ...
2 months ago · proactiveinvestors.com
OKYO Pharma reports positive Phase 2 results for urcosimod in neuropathic corneal painOKYO Pharma Ltd (NASDAQ:OKYO) on Wednesday reported promising top-line results from a Phase 2 trial of its investigational drug urcosimod for neuropathic corneal pain (NCP), with 75% of patients showi...